BIAL enters the US and acquires “promising” Parkinson’s disease programmes

News

Author: Simge Eva DoganPublished: 8 October 2020

Prep: Cook: Serves:

BIAL Parkinson's research and development department

Portugal-based pharmaceutical company BIAL has launched a new research centre, BIAL Biotech, in Massachusetts, US, which will focus on genetically defined Parkinson’s disease.

BIAL has also announced that it has acquired the Parkinson’s disease research programmes of Lysosomal Therapeutics Inc, as well as its research and development team and clinical programme for LTI-291 – a therapy designed to treat a genetic form of the condition.

António Portela, executive president of BIAL, said: “Our entry into the US with the creation of BIAL Biotech and the acquisition of the promising programmes from LTI, is a decisive step towards the fulfilment of our mission to contribute to improving the quality of life of people worldwide.

“The development of this new research centre in the US, is a landmark of enormous relevance for us. We are investing in science and research, through our direct presence in one of the most important research hubs in the world and in one of the most promising areas of medicine.”

Lead image: research and development department at BIAL

Last Month

Next Month

Go Back

Share this story

Comments

Global update

Neurologists should ‘speak up’ about Covid vaccines for people with Parkinson’s, says study

Breaking barriers to vaccination in the Parkinson’s disease community

Leading MEP declares Parkinson’s “a European priority issue”

Campaigners advocate for better EU policy towards Parkinson’s

Reimagining Parkinson’s healthcare: a patient-focused plan

A recent report suggests eight ways to improve Parkinson’s treatment

Study suggests why neurons die in Parkinson’s disease

Researchers at the University of Córdoba, Spain, have discovered how a certain protein may be linked to death of dopamine-producing neurons associated with Parkinson’s. Using animal models of the condition to conduct their study, the team focused on the protein DJ-1 – whose link to Parkinson’s has previously been established, though its exact function was uncertain. The researchers compared neurons in the brains of mice that possessed the gene expressing DJ-1 with those that did not. The findings revealed that dysfunction or absence of the gene expressing the DJ-1 protein could trigger the ‘cell cycle’ (the process by which cells divide), which should not occur under normal conditions. Because neurons lack the capacity to divide, this causes them die – leading to the onset of symptoms linked with Parkinson’s. It is hoped that uncovering these details about the relationship between DJ-1’s absence and Parkinson’s may lead to the development of…

Researchers have finally identified brain cells linked to Parkinson’s disease

For decades, scientists have known that Parkinson’s is associated with the death of dopamine-producing cells in the brain. Now, researchers from the Broad Institute of MIT and Harvard, US, have discovered the specific subtype of brain cells that die in Parkinson’s disease. Using a technique called single-cell RNA signalling, which enables the individual analysis of cells within a tissue for activity and protein production, researchers identified 10 subtypes of dopamine-producing cells within the donated brains of people who died from causes unrelated to Parkinson’s. The team carried out the same investigation on people who had died with Parkinson’s or a condition with similar symptoms called Lewy body dementia. They discovered that only one subtype of the cells had reduced in number – which suggests many of these cells had died while the people were living. It is hoped that the findings could lead to better understanding of Parkinson’s causes and…

Tiny DBS implant shows potential to advance Parkinson’s disease treatment

In an innovative trial by North Bristol NHS Trust, UK, surgeons have succeeded in implanting a tiny deep brain stimulation (DBS) device into a person’s skull. Their aim? To address symptoms of Parkinson’s. Designed with a tiny battery system that is inserted into the skull, the DBS device delivers electric impulses to targeted areas of the brain through electric probes. In doing so, it works to address abnormal brain cell activity associated with Parkinson’s – and may help to ease symptoms. One of around 25 patients selected for the year-long trial has described the device’s impact as “amazing”. Commenting on the results of the trial so far, consultant neurologist Dr Alan Whone of North Bristol NHS Trust said: “We are hopeful that if these findings hold up, we will have a significant technical advance by which to improve Parkinson’s care across the world.”

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Name
This field is for validation purposes and should be left unchanged.

BIAL enters the US and acquires “promising” Parkinson’s disease programmes

News

Author: Simge Eva DoganPublished: 8 October 2020

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Global update

Neurologists should ‘speak up’ about Covid vaccines for people with Parkinson’s, says study

Europe

Leading MEP declares Parkinson’s “a European priority issue”

Special reports

Reimagining Parkinson’s healthcare: a patient-focused plan

Study suggests why neurons die in Parkinson’s disease

Researchers have finally identified brain cells linked to Parkinson’s disease

Tiny DBS implant shows potential to advance Parkinson’s disease treatment

{title}

Subscribe

BIAL enters the US and acquires “promising” Parkinson’s disease programmes

News

Author: Simge Eva DoganPublished: 8 October 2020

Last Month

Next Month

Share this story

Comments

Related articles

Global update

Neurologists should ‘speak up’ about Covid vaccines for people with Parkinson’s, says study

Europe

Leading MEP declares Parkinson’s “a European priority issue”

Special reports

Reimagining Parkinson’s healthcare: a patient-focused plan

Study suggests why neurons die in Parkinson’s disease

Researchers have finally identified brain cells linked to Parkinson’s disease

Tiny DBS implant shows potential to advance Parkinson’s disease treatment

{title}

Subscribe

Sign in